Clinical trial
The Utility of Insulin Glargine (Lantus) Compared to NPH in Ethnic Minority Type 2 Diabetic Subjects Starting Insulin Therapy
NCT00686712 is registered in ClinicalTrials.gov with Charles Drew University of Medicine and Science as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- The Utility of Insulin Glargine (Lantus) Compared to NPH in Ethnic Minority Type 2 Diabetic Subjects Starting Insulin Therapy
- Lead sponsor
- Charles Drew University of Medicine and Science
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- February 28, 2003
- Completion date
- August 31, 2009
- Enrollment
- 108 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
type 2 diabetes mellitus